Twist Bioscience Incorporates MOLCURE AI Technology to Augment Therapeutic Antibody DiscoveryBusiness Wire • 07/26/21
Twist Bioscience Now Shipping Synthetic RNA Positive Controls for Delta (B.1.617.2) SARS-CoV-2 Variant for Development of Accurate Diagnostic TestsBusiness Wire • 07/22/21
Twist Bioscience to Report Fiscal 2021 Third Quarter Financial Results on Friday, August 6, 2021Business Wire • 07/21/21
Forensic Value Stock Selections: Top Positive And Negative Scoring Stocks For Mid-Year 2021Seeking Alpha • 07/06/21
Twist Bioscience Collaborates with Regeneron for Production of Genotyping by Sequencing Panel to Enable Diverse Genome-wide ScreeningBusiness Wire • 06/14/21
Twist Bioscience Begins Shipping of Synthetic RNA Controls for Kappa (B.1.617.1) SARS-CoV-2 Variants for Development of Accurate TestsBusiness Wire • 06/08/21
Twist Bioscience Launches Enzymatic Fragmentation Library Preparation Kit for High Uniformity, High-Yield Amplification, Streamlined Next Generation Sequencing Workflow for Targeted ApplicationsBusiness Wire • 05/25/21
Twist Bioscience Supports the Engineering Biology Research Consortium as it Publishes Statement of EthicsBusiness Wire • 05/13/21
Twist Bioscience Corporation (TWST) CEO Dr. Emily Leproust on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/08/21
Twist Bioscience and Vivlion Partner to Generate gRNA Libraries for CRISPR ApplicationsBusiness Wire • 04/28/21
Twist Bioscience to Report Fiscal 2021 Second Quarter Financial Results on Thursday, May 6, 2021Business Wire • 04/22/21